Step-down of inhaled corticosteroids in non-eosinophilic asthma: A prospective trial in real life. by Demarche, Sophie et al.
OR I G I N A L A R T I C L E
Asthma and Rhinitis
Step-down of inhaled corticosteroids in non-eosinophilic
asthma: A prospective trial in real life
S. Demarche1,2 | F. Schleich1 | M. Henket1 | V. Paulus1 | R. Louis1 | T. Van Hees2
1Department of Respiratory Medicine, CHU
Liege, GIGA I3 Research Group, University
of Liege, Liege, Belgium
2Department of Clinical Pharmacy, CIRM
(Center for Interdisciplinary Research on
Medicines), University of Liege, Liege,
Belgium
Correspondence
Sophie Demarche, Department of
Respiratory Medicine, CHU Liege, GIGA I3




This work was supported by a federal grant
IAP (“Interuniversity Attraction Poles”
programme) P7/30.
Summary
Background: While non-eosinophilic asthmatics are usually considered poorly
responsive to inhaled corticosteroids (ICSs), studies assessing a step-down of ICS in
this specific population are currently lacking.
Objectives: To assess the proportion of non-eosinophilic asthmatics in whom ICS
may be withdrawn without any clinical degradation and to determine the predictive
markers of a failure to stop treatment with ICS.
Methods: This prospective study was completed by 36 non-eosinophilic asthmatics,
defined by sputum eosinophils <3% and blood eosinophils <400/lL. In these
patients, whichever the baseline asthma control level, the dose of ICS was gradually
reduced every 3 months until they met the failure criteria or successfully discontin-
ued ICS for 6 months. The failure criteria were an ACQ score ≥1.5 with an increase
from baseline >0.5 or a number of severe exacerbations during the study which was
greater than the number during the year prior to the baseline visit. Receiver-operat-
ing characteristic (ROC) curves were constructed to assess predictors of a failure to
stop ICS. This study is registered with ClinicalTrials.gov, number NCT02169323.
Results: In 14 patients (39%), ICSs were completely withdrawn, and in 10 further
patients (28%), ICS were stepped-down to a reduced ICS dose without any deterio-
ration of asthma control and exacerbation rate. Baseline predictors of a failure to
stop ICS were a greater age (area under ROC curve [ROC AUC] and [95% CI]: 0.77
[0.62-0.93]) and elevated blood eosinophils (ROC AUC [95% CI]: 0.77 [0.61-0.93]).
After the first step-down of ICS, the best predictor was an elevated blood eosino-
phil count (ROC AUC [95% CI]: 0.85 [0.72-0.99]).
Conclusions & Clinical Relevance: Withdrawing or reducing the dose of ICS is feasi-
ble in two-thirds of non-eosinophilic asthmatics irrespective of baseline asthma con-
trol. An elevated blood eosinophil count may predict the failure to stop ICS.
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1 | INTRODUCTION
Asthma is a heterogeneous disease, which can be classified into
various phenotypes according to clinical, inflammatory or physio-
logic characteristics, treatment responsiveness and prognostic fac-
tors.1 The technique of induced sputum has allowed to define 2
inflammatory phenotypes: eosinophilic and non-eosinophilic
asthma.2
According to international guidelines, ICSs are the first-line con-
troller treatment in asthmatic patients,3 whichever their inflamma-
tory phenotype. Non-eosinophilic asthmatics are, however, usually
considered poorly responsive to ICS.4 Several studies have indeed
shown that the effect of short-term treatment with ICS on symp-
toms, quality of life, baseline airway calibre and bronchial hyperre-
sponsiveness was lower in non-eosinophilic asthmatics as compared
with their eosinophilic counterparts.5-8 Whether these non-eosino-
philic asthmatics are unresponsive,5,6 partly responsive7,8 or well
responsive9 to ICS is still controversial. This is, however, an impor-
tant concern because they account for approximately 60% of corti-
costeroid-naive asthmatic patients when the threshold to define
sputum eosinophilia is set at 3%.10
In studies assessing the impact of discontinuing or reducing the
dose of ICS in controlled asthmatics, increased sputum eosinophils at
baseline11,12 or a raise in sputum eosinophils during the step-
down13-15 was found to be predictive markers for asthma deteriora-
tion. These studies had, however, included both eosinophilic and
non-eosinophilic patients. Nevertheless, it has been suggested that
stepping-down ICS in eosinophilic asthmatics might put those
patients at risk of exacerbations.11 A step-down of ICS may, how-
ever, be acceptable in non-eosinophilic asthmatics,16 but studies in
this specific population are currently lacking.
The aims of our study were twofold. First, to assess the propor-
tion of non-eosinophilic patients in whom ICS may be withdrawn
without any degradation of asthma control and exacerbation rate
and second, to determine the predictive markers of a failure to stop
treatment with ICS.
2 | METHODS
2.1 | Setting and participants
Patients were recruited from the University Asthma Clinic of Liege,
between 20 June 2014 and 30 June 2016. The diagnosis of asthma
was defined by the presence of typical symptoms (wheezing, breath-
lessness, chest tightness, cough) and at least one of the following
criteria: a forced expiratory volume in 1 second (FEV1) increase of at
least 12% and 200 mL after inhalation of 400 lg salbutamol and/or
a provocative concentration of methacholine causing a 20% fall in
FEV1 less than 16 mg/mL. Patients were eligible for the study if they
were asthmatics aged of at least 18 years, had a sputum eosinophil
count <3% combined with a blood eosinophil count <400/lL17 and
were treated with ICS at the same dose since the previous
3 months. Patients were excluded if they had a history of near-fatal
asthma requiring a stay in intensive care unit, if they were treated
with oral corticosteroids (OCSs) at screening visit or had been trea-
ted with OCS in the previous 4 weeks, if they were treated with
omalizumab or if they were pregnant women. The study was
approved by the Ethics Committee of the University Hospital of
Liege (Reference 2014/98) and registered with ClinicalTrials.gov,
number NCT02169323. All patients gave written informed consent.
2.2 | Study design
The study was prospective, monocentric and interventional. The
study design is shown in Figure 1.
Before stepping-down ICS, an intermediate phase of treatment
step-up was performed at the beginning of the study in patients
whose asthma was uncontrolled despite a low or medium dose of
ICS. In these asthmatics, the treatment was stepped-up to the GINA
step 4 with a high dose of ICS for 3 months. This stage was included
in the study design to ensure that each patient was treated in accor-
dance with the international guidelines before stepping-down the
ICS dose. This step-up phase also gave us the opportunity to study
the impact of an increased dose of ICS in symptomatic non-eosino-
philic asthmatics.
For all study patients, the intervention consisted of a progressive
step-down of ICS every 3 months according to the dose levels
defined by the GINA guidelines (from a high dose to a medium dose
to a low dose to a complete cessation) until the patients met the
failure criteria (see below) or discontinued ICS for 6 months. The
visit preceding the first step-down was considered as the baseline
visit. At each 3-month visit or whenever during the study on request
by the patient, the ACQ score and the number of severe exacerba-
tions were assessed to determine the pursuit of the study. This
assessment was always performed outside an asthma exacerbation.
An ACQ score ≥1.5 with an increase from the baseline score by
more than 0.5 point and/or a cumulated number of severe exacerba-
tions from baseline greater than the number of severe exacerbations
during the year prior to the baseline visit were deemed as failure cri-
teria in the study. Patients meeting at least one of these criteria
were therefore withdrawn from the study and were prescribed an
adequate dose of ICS. Patients who did not meet the failure criteria
continued the study protocol.
As described in Figure 1, patients had a detailed investigation at
study entry, at each 3-month visit and at the last visit. If patients
had a severe exacerbation at any of these scheduled visits, the
detailed investigation was postponed and performed at least
4 weeks after the last dose of OCS.
2.3 | Study investigations
Atopy was defined as the presence of 1 or more positive specific
IgE (>0.35 kU/L) to at least one of the following aeroallergens: cat,
dog, grass pollen, tree pollen, house dust mite and a mould mixture
(Phadia, Groot-Bijgaarden, Belgium). Fractional exhaled nitric oxide
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(FENO) was measured at a flow rate of 50 mL/s (NIOX; Aerocrine,
Solna, Sweden). Sputum induction and processing with the whole-
sample technique was performed as previously described.18 The
technician who performed the sputum cell count was blind to the
clinical status of patients. Asthma control was assessed by the
Asthma Control Test (ACT)19 and Asthma Control Questionnaire
(ACQ)20 scores. Asthma-related quality of life was measured by the
Mini Asthma Quality of Life Questionnaire (Mini-AQLQ) score.21 The
Shortened version of the Inhaled Corticosteroids side-effect Ques-
tionnaire (ICQ-S) was used to monitor side-effects of ICS.22 The
ICQ-S score ranges from 0 (no side-effect) to 90 (highest levels of
side-effects).22 The adherence to ICS was measured by the 5-item
Medication Adherence Report Scale (MARS-5) score.23,24 The
MARS-5 score ranges from 5 (the worst) to 25 (the best adher-
ence).23 The inhalation technique for ICS was checked at each visit,
and the number of errors was recorded. A severe exacerbation was
defined as the use of systemic corticosteroids during at least 3 days
or a hospitalization/emergency room visit due to asthma with use of
systemic corticosteroids.25 We recorded the number of severe exac-
erbations during the year prior to the baseline visit and throughout
the study. At the end of the study, the total number of exacerba-
tions recorded after the baseline visit was annualized. The routine
laboratory of the University Hospital of Liege performed the blood
cell count and the analysis of C-reactive protein (CRP) and fibrino-
gen.
2.4 | Statistical analysis
Data were presented as number of observations and percentages for
categorical variables and as mean  standard deviation or median
(interquartile range) for continuous variables. Data from 2 indepen-
dent groups were compared using a chi-square or Fisher’s exact test
for categorical variables, a t test for continuous variables compatible
with a normal distribution or a Mann-Whitney test for continuous
variables incompatible with a normal distribution. To compare 2 vis-
its of the same patients, we used a McNemar test for binary vari-
ables, a paired t test for continuous variables when the differences
were compatible with a normal distribution or a Wilcoxon matched-
pairs signed-rank test for continuous variables when the differences
were not compatible with a normal distribution. The ability of vari-
ables to predict an improvement after a treatment step-up or to pre-
dict a failure to stop ICS was assessed by constructing receiver-
operating characteristic (ROC) curves, and optimal thresholds were
determined by the method of the nearest point to (0, 1). For the
variables in each Table, when the number of missing values
exceeded 10%, the number of observations was stated in the
Detailed invesgaon at each 3-month visit:
▪ FENO
▪ Spirometry (pre and post-bronchodilator)
▪ Sputum inducon
▪ ACT, ACQ, Mini-AQLQ
▪ ICQ-S
▪ MARS-5 (when ICS treatment)
▪ Inhalaon technique (when ICS treatment)
▪ Blood sampling
Failure and success criteria
Study suspended for paents meeng 
at least one of the failure criteria:
▪ ACQ ≥1.5 andACQ from baseline >0.5
▪ No. of severe exacerbaons since the 
baseline visit > no. during the year prior 
to the baseline visit
Protocol completed with the success 
criteria: 6-month follow-up without ICS and 
without meeng the failure criteria
ACQ ≥1.5 and treatment with a 
low or medium dose of ICS
ACQ <1.5
OR
ACQ ≥1.5 and GINA step 4 
treatment with a high dose of ICS
Study entry
Step-up to GINA step 4 








9 months6 months3 months
Step-down 3Step-down 2Step-down 1Baseline
Paents with a low 
ICS dose at baseline
Paents with a medium 
ICS dose at baseline
Paents with a high 
ICS dose at baseline
F IGURE 1 Schematic representation of the study design. ACQ, asthma control questionnaire; ACT, asthma control test; AQLQ, asthma
quality of life questionnaire; FENO, fractional exhaled nitric oxide; ICQ-S, shortened version of the Inhaled corticosteroids side-effect
questionnaire; ICS, inhaled corticosteroid; MARS-5, 5-item medication adherence report scale
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Table caption. A P value <.05 was considered statistically significant.
Statistical analysis was carried out using STATA version 13.0 (Statis-
tical Software; StataCorp LP, College Station, TX, USA). GraphPad
Prism version 7.03 (GraphPad Software, La Jolla, CA, USA) was used
for Figure 3.
3 | RESULTS
A total of 312 asthmatic patients were assessed for eligibility, of
whom 43 were included in the study and 36 completed the protocol
(Figure 2). From these patients, 14 were successfully weaned off
ICS, while 22 patients failed to stop ICS. The median time of follow-
up was 9 months (IQR: 5-13 months).
3.1 | Treatment step-up in uncontrolled patients
At study entry, 13 patients had an ACQ score ≥1.5 while not being
treated with a high dose of ICS. Overall in these patients, a treat-
ment step-up to the GINA step 4 with high-dose ICS did not result
in any functional, clinical or inflammatory changes, apart from a
reduction in FENO (P = .02, Table 1). We, however, noticed that 5
patients had a clinically significant improvement in asthma control
after this treatment step-up (defined as a decrease in ACQ >0.5
and/or an increase in ACT >3). These 5 patients were compared
with the remaining 8 patients regarding their characteristics at study
entry. Those with a significant improvement in asthma control had a
lower ACT score (mean  SD: 13  3 vs 17  3, P = .03) and a
higher FENO (median [IQR]: 34 [19-57] vs 13 [10-18] ppb, P = .04)
at study entry than patients without any improvement in asthma
control after the treatment step-up. The area under the ROC curve
(ROC AUC) to identify patients who benefited from a treatment
step-up was 0.86 for ACT (95% CI: 0.66-1.00), the best threshold
being <16 points (sensitivity: 80%, specificity: 75%, positive predic-
tive value [PPV]: 67%, negative predictive value [NPV]: 86%,
N = 13). The ROC AUC for FENO was 0.88 (95% CI: 0.66-1.00), the
best threshold being >20 ppb (sensitivity: 75%, specificity: 88%,
PPV: 75%, NPV: 88%, N = 12).
3.2 | Step-down of ICS
Demographic characteristics of all study patients are summarized in
Table 2. Functional, clinical, inflammatory and treatment characteris-
tics at baseline, after the first step-down, and at the last visit in
Adult asthmatics assessed for eligibility (N = 312) 
Excluded (N = 269)
▪ Not meeting inclusion criteria/meeting exclusion criteria (N = 267) 
- Unsuccessful sputum induction/analysis (N = 55) 
- Sputum eosinophils ≥3% (N = 119) 
- Blood eosinophils ≥400/μL (N = 11) 
- Untreated with ICS (N = 65) 
- Change in the ICS dose in the previous 3 months (N = 3) 
- Previous stay in ICU for asthma (N = 2) 
- OCS in the 4 weeks prior to the visit (N = 12) 
▪ Declined to participate (N = 2) 
Included (N = 43)
▪ Lost to follow-up (N = 1) 
▪ Withdrew consent (N = 5) 
- Time constraint (N = 1) 
- Unwilling to step-down ICS (N = 4) 
▪ Initiation of omalizumab (N = 1) 
Completed protocol with the 
success criteria (N = 14) 
Completed protocol with the 
failure criteria (N = 22) 
 
F IGURE 2 Flow diagram (adapted from
the CONSORT flow diagram). ICS, inhaled
corticosteroid; ICU, intensive care unit;
OCS, oral corticosteroid
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patients with a successful and unsuccessful withdrawal of ICS are
presented in Table 3.
At baseline, patients who subsequently failed to be weaned off
ICS were older and had higher blood eosinophils than patients who
successfully stopped ICS (P = .006 for both comparisons; Table 2
and Table 3, respectively).
A successful withdrawal of ICS (N = 14) was concomitant with
an improvement in ACT, a reduced rate of severe exacerbations and
a decreased number of blood neutrophils as compared with the
baseline visit (Table 3). In this subgroup of 14 patients, 5 (36%) had
a clinically significant improvement in asthma control (defined as a
decrease in ACQ >0.5 and/or an increase in ACT >3) when ICS
treatment was withdrawn. As compared with the 9 other patients of
this subgroup, those with an improved asthma control when ICSs
were stopped had a higher baseline reversibility (median [IQR]: 6 [5-
8] vs 3 [1-4]%, P = .03), a lower baseline ACT score (mean  SD:
14  4 vs 20  4, P = .01), a higher baseline ACQ score
(mean  SD: 2.6  0.9 vs 0.8  0.8, P = .003), a lower baseline
TABLE 1 Patient characteristics and effect of treatment step-up in uncontrolled non-eosinophilic asthmatics treated with a low or medium
dose of ICS at study entry
Non-eosinophilic asthmatics with an ACQ ≥1.5 and treated with a low or medium dose of ICS at study entry (N = 13)
Age, years 54 (50-65)
Women, N (%) 7 (54)
Atopy, N (%) 4 (31)
Age of asthma onset, years 45 (23-54)
BMI, kg/m² 28.8  5.7
Smoking status, N (%)
Non-smokers 4 (31)
Current smokers 3 (23)
Ex-smokers 6 (46)
Visit before step-up Visit after step-up P value
FEV1, % predicted 81.5  15.7 82.7  15.3 .70
FVC, % predicted 86.4  16.0 90.9  20.6 .28
FEV1/FVC, % 78.1  6.9 76.2  11.5 .55
Reversibility, % 2 (-1-6) 5 (2-7) .51
ACT 15  3 17  4 .31
ACQ 2.4  0.7 2.2  0.8 .17
Mini-AQLQ 4.0  0.8 4.3  0.9 .40
FENO, ppb 17 (12-33) 13 (6-20) .02
Sputum eosinophils, %a 0.6 (0.2-1.0) 0.6 (0.2-2.0) .68
Sputum eosinophils, 910³/ga 6 (2-18) 12 (3-32) .22
Sputum neutrophils, %a 77 (65-90) 73 (47-79) .13
Sputum neutrophils, 910³/ga 1444 (971-1627) 1385 (314-3543) .96
Blood eosinophils,/lL 109 (77-178) 124 (78-172) .31
Blood neutrophils,/lL 3911 (2611-4838) 4403 (3038-5159) .13
CRP, mg/L 2.7 (1.4-5.3) 1.8 (0.3-4.9) .23
Fibrinogen, g/L 3.1 (2.7-4.0) 2.9 (2.7-3.9) .83
ICS dose (BDP CFC equivalents) 800 (500-800) 2000 (2000-2000) —
LABA, N (%) 11 (85) 13 (100) .50
LTRA, N (%) 3 (23) 3 (23) 1.0
Theophylline, N (%) 1 (8) 1 (8) 1.0
ICQ-Sb 34 (25-43) 31 (28-44) .95
ACQ, asthma control questionnaire; ACT, asthma control test; AQLQ, asthma quality of life questionnaire; BDP CFC, beclomethasone dipropionate–chlo-
rofluorocarbon; BMI, body mass index; CRP, C-reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity; ICQ-S, shortened version of the inhaled corticosteroids side-effect questionnaire; ICS, inhaled corticosteroid; LABA, long-acting b2-
agonist; LTRA, leukotriene receptor antagonist.
aData available for both visits in 10 patients.
bData available for both visits in 9 patients.
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mini-AQLQ score (mean  SD: 3.8  0.8 vs 6.0  0.9, P = .0008), a
trend towards higher baseline blood neutrophils (median [IQR]: 5159
[4482-5841] vs 3938 [2957-4212]/lL, P = .053) and a trend
towards higher dose of ICS at baseline (median [IQR]: 2000 [1600-
2000] vs 1000 [400-1000] BDP equivalents, P = .058). Among the 9
patients whose asthma control did not improve when ICSs were
stopped, it should be noted that 3 patients had sputum eosinophils
≥3% at least once during the study.
In patients who failed to stop ICS (N = 22), their last visit was
associated with a worsening in FEV1, forced vital capacity (FVC),
reversibility to salbutamol, ACQ, sputum eosinophils and blood fib-
rinogen as compared with baseline (Table 3). In those patients in
whom a complete cessation of ICS was unsuccessful, a step-down to
a reduced ICS dose was, however, possible without meeting the fail-
ure criteria in 10 patients (45%). In this subgroup, the ICS dose was
reduced by a median (IQR) of 1000 (400-1600) lg beclomethasone
CFC equivalents. It is also worth noting that all patients who had an
improvement in asthma control after the treatment step-up and who
completed the protocol failed to completely stop ICS.
When looking at the evolution of clinical and inflammatory out-
comes throughout the study, the loss of asthma control was con-
comitant with increased blood and sputum eosinophils in patients
who failed to stop of ICS, whereas these inflammatory parameters
were rather stable over time in patients who successfully discontin-
ued ICS (Figure 3).
In a subgroup analysis, we assessed the success rate of ICS ces-
sation according to the level of asthma control at baseline. In the
subgroup of patients with an ACQ <1.5 at baseline, ICSs were suc-
cessfully withdrawn in 40% of patients (8 of 20), while the success
rate was 38% (6 of 16) in the subgroup of patients with an ACQ
≥1.5 at baseline despite treatment with high-dose ICS.
We also analysed the success rate of ICS cessation according to
the season at last visit of patients. The success rate was 50% (4 of
8) in patients whose last study visit was in summer, 45% (5 of 11) in
patients with a last visit in spring, 14% (1 of 7) in patients with a last
visit in autumn and 40% (4 of 10) in patients who finished the study
in winter (P = .54 for the comparison).
3.3 | Predictors of a failure to stop ICS
ROC analyses for predictors of an unsuccessful withdrawal of ICS
are presented in Table 4. Predictors at baseline and after the first
step-down correspond to the variables that were statistically differ-
ent between the success and failure groups at these time-points. At
baseline, a greater age and elevated blood eosinophils were found to
be predictive of a failure to stop ICS (area under ROC curve: 0.77
for both predictors, Table 4). After the first step-down, an elevated
number of blood eosinophils were the best predictor of an unsuc-
cessful withdrawal of ICS (area under ROC curve: 0.85, Table 4). A
subanalysis of the failure rate of ICS withdrawal according to several
thresholds of blood eosinophils at baseline and after the first step-
down was also performed and is shown in Table 5. To find individual
predictors of a failure to stop ICS, we compared the absolute
changes in the continuous variables of Table 3 from baseline to first
step-down between both groups of patients. The variation in the
ACQ score was the only variable that was statistically significant
between both groups of patients, and its ability to predict an unsuc-
cessful withdrawal of ICS is presented in Table 4 (area under ROC
curve: 0.76).
In the subgroup of patients who had an ACQ ≥1.5 despite treat-
ment with high-dose ICS before the step-down, predictors at base-
line of a failure to stop ICS were a greater age and elevated blood
eosinophils, while the only predictor after the first step-down was
an elevated blood eosinophil count (Table 6).
3.4 | Adherence to ICS and inhalation technique
At each visit (except when patients were weaned off ICS), the
adherence and inhalation technique were measured for ICS. Adher-
ence to ICS was good in both groups at baseline (median MARS-5
TABLE 2 Demographic characteristics of all study patients and comparison between patients with a successful and unsuccessful withdrawal
of ICS
All
Patients with a successful
withdrawal of ICS
Patients with an unsuccessful
withdrawal of ICS
P value, successful vs unsuccessful
withdrawal of ICS
N 36 14 22 —
Age, years 53 (41-64) 46 (33-53) 62 (48-66) .006
Women, N (%) 22 (61) 9 (64) 13 (59) .76
Atopy, N (%) 21 (58) 7 (50) 14 (63) .42
Age of asthma onset,
years
25 (9-53) 23 (8-45) 32 (10-56) .49
BMI, kg/m² 27.5  5.5 27.1  5.7 27.8  5.5 .75
Smoking status, N (%) 1.0
Non-smokers 16 (44) 6 (43) 10 (45)
Current smokers 5 (14) 2 (14) 3 (14)
Ex-smokers 15 (42) 6 (43) 9 (41)
BMI, body mass index; ICS, inhaled corticosteroid.
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score [IQR]: 24 [21-25] in the success group and 25 [23-25] in the
failure group) and at subsequent visits (median MARS-5 score
[IQR]: 24 [23-25] in the success group and 25 [24-25] in the fail-
ure group). The median (IQR) number of errors in the inhalation
technique was 1 (0-2) for both groups at baseline and was 0 (0-1)
in the success group and 1 (0-1) in the failure group at subsequent
visits.
4 | DISCUSSION
The importance of personalized medicine has been largely empha-
sized over recent years. Corticosteroid responsiveness in asthma is
certainly a major issue in this regard. In corticosteroid-naive patients,
the presence of eosinophilic airway inflammation seems necessary to
have a good clinical response to ICS. Our study shows that step-
ping-down ICS in non-eosinophilic asthmatics is feasible in clinical
practice irrespective of baseline asthma control. About one-third of
the patients can be completely weaned off ICS while 1 further third
can be stepped-down to a reduced ICS dose without compromising
asthma control and exacerbation rate. In those patients who are get-
ting uncontrolled when withdrawing ICS, it is of interest that blood
eosinophil count may alert the clinician to the risk of asthma deterio-
ration.
Although the major aim of our study was to investigate the step-
down of ICS in non-eosinophilic asthmatics, an intermediate phase
of step-up was included in our protocol for those patients who were
uncontrolled at study entry despite a treatment with a low or mod-
erate dose ICS. While this step-up did not result in any overall clini-
cal improvement when the whole subgroup was analysed, it is
noteworthy that those individual patients with higher FENO levels
had a clinically significant improvement in asthma control (defined as
a decrease in ACQ >0.5 and/or an increase in ACT >3)3 with an
increased dose of ICS. These data are in keeping with several studies
showing that some steroid-naive non-eosinophilic patients might
benefit from ICS,8,9,26 particularly those with increased FENO
levels.8
It has been suggested that sputum11-15 and blood15 eosinophils
may predict asthma deterioration following a decrease or withdrawal
of ICS in well-controlled asthmatics. In non-eosinophilic patients
defined by sputum eosinophils <3% and blood eosinophils <400/lL,
our data show that elevated blood eosinophils at baseline and ele-
vated blood or sputum eosinophils after the first step-down phase
were predictive of a failure to withdraw ICS. As previously sug-
gested,27 a low-grade eosinophilic inflammation may therefore exist
in non-eosinophilic asthmatics and may explain an unsuccessful with-
drawal of ICS. As far as FENO is concerned, it did not predict a fail-
ure to stop ICS in our study, in accordance with previous
findings.13,14
International guidelines recommend to step-down treatment
once asthma control has been achieved for at least 3 months.3 How-
ever, in keeping with studies tailoring asthma treatment according to
sputum eosinophils,16,28 we chose to step-down ICS in non-eosino-
philic asthmatics irrespective of baseline asthma control. It is there-
fore worth noting that one-third of uncontrolled asthmatics despite
treatment with high-dose ICS at baseline were successfully weaned
off ICS without any clinical degradation. Besides, monitoring sputum
eosinophils during the step-down process is of importance because
some patients may tolerate an increase in sputum eosinophils with-
out any degradation in asthma control, as previously reported.18,29 In
those patients, the ICS dose should be raised to reduce the risk of
exacerbations associated with eosinophilic inflammation.30,31
F IGURE 3 ACQ score (A), absolute blood eosinophil count (B)
and sputum eosinophil percentage (C) at baseline, after the first
step-down and at the last visit in patients with a successful and
unsuccessful withdrawal of ICS. Data are expressed as mean (SD) for
ACQ and median (IQR) for blood and sputum eosinophils. * P < .05,
(*) P = .05. ACQ, asthma control questionnaire; ICS, inhaled
corticosteroid
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Several systematic reviews and meta-analyses of randomized
controlled trials assessing the step-down of ICS have been published
so far. Rank et al32 reported that withdrawing low-dose ICS was
associated with a higher risk of exacerbations, which occurred in
38% of those patients over a mean period of 6 months. In contrast,
Hagan et al33 suggested that reducing ICS to a lower dose did not
increase the risk of asthma exacerbations while in a recent article,
Crossingham et al34 concluded that the body of evidence was insuf-
ficient to draw conclusions about the risks and benefits of stepping-
down ICS. In these studies, the prevalence of exacerbations was
21% and 18%, respectively, over a mean follow-up of 5-6 months in
patients whose ICSs were reduced. These results are, however, not
comparable with our data, where we found that stepping-down ICS
was unsuccessful in 33% of patients, as the failure criteria in our
TABLE 4 ROC analysis for predictors of a failure to stop ICS
N AUC 95% CI Best threshold Sensibility Specificity PPV NPV
Predictors at baseline
Age, years 36 0.77 0.62-0.93 >59 59% 93% 93% 59%
Blood eosinophils,/lL 36 0.77 0.61-0.93 >110 68% 86% 88% 63%
Predictors after the first step-down
ACQ 35 0.79 0.61-0.96 >1.5 86% 71% 82% 77%
ACT 35 0.73 0.54-0.92 <20.5 86% 64% 78% 75%
Mini-AQLQ 35 0.70 0.51-0.89 <4.8 71% 64% 75% 60%
Sputum eosinophils, % 34 0.73 0.56-0.90 >0.9% 65% 86% 87% 63%
Blood eosinophils,/lL 35 0.85 0.72-0.99 >141 81% 86% 89% 75%
Predictors based on the change from baseline to the first step-down
Change in ACQ 35 0.76 0.60-0.92 >0.2 57% 93% 92% 59%
ACQ, asthma control questionnaire; ACT, asthma control test; AQLQ, asthma quality of life questionnaire; AUC, area under the curve; NPV, negative
predictive value; PPV, positive predictive value.
TABLE 5 Failure rate of ICS




unsuccessful withdrawal of ICS, N (%)
Blood eosinophils at baseline
Blood eosinophils <100/lL 14 5 (36)
Blood eosinophils <150/lL 24 12 (50)
Blood eosinophils <200/lL 28 15 (54)
Blood eosinophils <300/lL 34 20 (59)
Blood eosinophils <400/lL 36 22 (61)
Blood eosinophils after the first step-down
Blood eosinophils <100/lL 10 2 (20)
Blood eosinophils <150/lL 17 5 (29)
Blood eosinophils <200/lL 26 13 (50)
Blood eosinophils <300/lL 31 17 (55)
Blood eosinophils <400/lL 33 19 (58)
TABLE 6 ROC analysis for predictors of a failure to stop ICS in patients with a baseline ACQ ≥1.5 despite treatment with high-dose ICS
N AUC 95% CI Best threshold Sensibility Specificity PPV NPV
Predictors at baseline
Age, years 16 0.91 0.77-1.00 >53 80% 83% 89% 71%
Blood eosinophils,/lL 16 0.87 0.69-1.00 >121 70% 100% 100% 67%
Predictors after the first step-down
Blood eosinophils,/lL 16 0.83 0.62-1.00 >108 80% 83% 89% 71%
AUC, area under the curve; ICS, inhaled corticosteroids; NPV, negative predictive value; PPV, positive predictive value.
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study included both exacerbations and worsening in asthma control.
Moreover, in studies included in these meta-analyses, patients were
selected based on a good asthma control but not according to their
eosinophilic phenotype. However, we are convinced that the step-
down approach in these studies would have been more effective if
sputum eosinophils had been taken into account.
Remarkably, in our study, an improvement in asthma control and
a reduction in exacerbation rate were observed in patients who were
successfully weaned off ICS. The reasons for this improvement are
unclear, but one can hypothesize that local side-effects and reduced
local immunity with ICS might play a role. Although withdrawing ICS
was not possible in 60% of the study population, a reduction in the
ICS dose was feasible in half of these patients without clinical degra-
dation over a 3-month period. In clinical practice, the importance to
find the lowest effective treatment with ICS is explained by the fact
that high-dose ICSs are associated with local and systemic side-
effects,35,36 increased risk of respiratory infections37,38 and costs.
A strength of our study is that there are currently little data in
the literature on ICS step-down in non-eosinophilic asthmatics.
Moreover, the time of follow-up was reasonably long in our proto-
col, with step-down phases every 3 months and an observation time
of patients without ICS of 6 months.
Our study has some limitations. First, non-eosinophilic asthmat-
ics were defined based on a single measurement of sputum and
blood eosinophils at baseline. Therefore, we cannot exclude that a
part of the study patients had intermittently eosinophilic asthma,
a phenotype known to partly respond to corticosteroids.39 Second,
because all patients defined as non-eosinophilic at study entry
were treated with ICS when sputum and blood were sampled, we
acknowledge that a part of our study population was probably
misclassified as non-eosinophilic. This was confirmed by the fact
that some patients showed a recrudescence of eosinophilic inflam-
mation when ICSs were stepped-down. A way to correctly assess
the inflammatory phenotype of patients would have been to mea-
sure sputum and blood eosinophils during a steroid withdrawal
step at study entry, but this was impracticable in a real-life clinical
trial. Third, our study had no control group, which means that we
could not compare our results with those obtained in a group of
patients who were kept on a stable dose of ICS. Fourth, our
study was not blinded and we may hypothesize that the failure
rate would have been lower in a blinded study, which may be
explained by the presence of some patients anxious to be
deprived of a chronic treatment supposed to be essential for con-
trolling their disease. Fifth, our study was not powered to assess
the impact of seasonal changes on the success rate of the step-
down process, but we can hypothesize that such changes might
contribute to the failure to stop ICS in some patients. Finally, as
it was a monocentric study, the number of included patients was
quite limited, despite a fair number of screened patients.
In conclusion, our data provide evidence that stopping or reduc-
ing the dose of ICS may be possible irrespective of baseline asthma
control in a substantial part of non-eosinophilic asthmatics without
compromising asthma control and the risk of exacerbations. This
finding, which challenges the current international recommendations,
urgently needs to be confirmed in large prospective multicentre ran-
domized controlled trials.
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